Generics in the United Kingdom - Market Summary, Competitive Analysis and Forecast to 2025

Publication ID:

MLI06211475

Publication Date:

July 13, 2021

Pages:

Publisher:

MarketLine

Countries:

United Kingdom [1]

USD 350.00

Generic Drugs [2]

Pharma & Healthcare [3]

Description:

Generics in the United Kingdom - Market Summary, Competitive Analysis and Forecast to 2025

Summary

Generics in the United Kingdom industry profile provides top-line qualitative and quantitative summary information including: market size (value 2016-20, and forecast to 2025). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The UK generics market had total revenues of $13.7bn in 2020, representing a compound annual growth rate (CAGR) of 7.2% between 2016 and 2020.
- Market consumption volume increased with a CAGR of 2% between 2016 and 2020, to reach a total of 86.6% in 2020.
- The key factors driving the growth of generic drug usage are incentives for the purchase of generics and expanded prescription quotas for GPs and specialists.

Scope

- Save time carrying out entry-level research by identifying the size, growth, major segments, and leading players in the generics market in the United Kingdom
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United Kingdom
- Leading company profiles reveal details of key generics market players鈥� global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United Kingdom generics market with five year forecasts

Reasons to Buy

- What was the size of the United Kingdom generics market by value in 2020?
- What will be the size of the United Kingdom generics market in 2025?
- What factors are affecting the strength of competition in the United Kingdom generics market?
- How has the market performed over the last five years?
- What are the main segments that make up the United Kingdom's generics market?

Table Of Contents:

Table of Contents
1 Executive Summary
1.1. Market value
1.2. Market value forecast
1.3. Market volume
1.4. Market volume forecast
1.5. Geography segmentation
1.6. Market rivalry
1.7. Competitive Landscape
2 Market Overview
2.1. Market definition
2.2. Market analysis
3 Market Data
3.1. Market value
3.2. Market volume
4 Market Segmentation
4.1. Geography segmentation
5 Market Outlook
5.1. Market value forecast
5.2. Market volume forecast
6 Five Forces Analysis
6.1. Summary
6.2. Buyer power
6.3. Supplier power
6.4. New entrants
6.5. Threat of substitutes
6.6. Degree of rivalry
7 Competitive Landscape
7.1. Who are the leading players?
7.2. What are the strengths/weaknesses of the leading players?
7.3. Has there been any significant recent M&A activity?
7.4. How has the COVID-19 pandemic impacted leading players?
8 Company Profiles
8.1. Teva Pharmaceutical Industries Limited
8.2. Viatris Inc.
8.3. Pfizer Inc.
9 Macroeconomic Indicators
9.1. Country data
10 Appendix
10.1. Methodology
10.2. Industry associations
10.3. Related MarketLine research
10.4. About MarketLine

List of Tables
List of Tables
Table 1: United Kingdom generics market value: $ billion, 2016-20
Table 2: United Kingdom generics market volume: %, 2016-20
Table 3: United Kingdom generics market geography segmentation: $ billion, 2020
Table 4: United Kingdom generics market value forecast: $ billion, 2020-25
Table 5: United Kingdom generics market volume forecast: %, 2020-25
Table 6: Teva Pharmaceutical Industries Limited: key facts
Table 7: Teva Pharmaceutical Industries Limited: Annual Financial Ratios
Table 8: Teva Pharmaceutical Industries Limited: Key Employees
Table 9: Viatris Inc.: key facts
Table 10: Viatris Inc.: Annual Financial Ratios
Table 11: Viatris Inc.: Key Employees
Table 16: Pfizer Inc.: key facts
Table 17: Pfizer Inc.: Annual Financial Ratios
Table 18: Pfizer Inc.: Key Employees
Table 19: Pfizer Inc.: Key Employees Continued
Table 20: United Kingdom size of population (million), 2016-20
Table 21: United Kingdom gdp (constant 2005 prices, $ billion), 2016-20
Table 22: United Kingdom gdp (current prices, $ billion), 2016-20
Table 23: United Kingdom inflation, 2016-20
Table 24: United Kingdom consumer price index (absolute), 2016-20
Table 25: United Kingdom exchange rate, 2016-20

List of Figures
List of Figures
Figure 1: United Kingdom generics market value: $ billion, 2016-20
Figure 2: United Kingdom generics market volume: %, 2016-20
Figure 3: United Kingdom generics market geography segmentation: % share, by value, 2020
Figure 4: United Kingdom generics market value forecast: $ billion, 2020-25
Figure 5: United Kingdom generics market volume forecast: %, 2020-25
Figure 6: Forces driving competition in the generics market in the United Kingdom, 2020
Figure 7: Drivers of buyer power in the generics market in the United Kingdom, 2020
Figure 8: Drivers of supplier power in the generics market in the United Kingdom, 2020
Figure 9: Factors influencing the likelihood of new entrants in the generics market in the United Kingdom, 2020
Figure 10: Factors influencing the threat of substitutes in the generics market in the United Kingdom, 2020
Figure 11: Drivers of degree of rivalry in the generics market in the United Kingdom, 2020

Companies Mentioned:

Teva Pharmaceutical Industries Limited
Viatris Inc.
Pfizer Inc.

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂